• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    2/9/23 11:25:13 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email
    SC 13G/A 1 tv01359-mannkindcorp.htm SCHEDULE 13G/A mannkindcorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  MannKind Corp.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  56400P706

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  56400P706

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    195,007

    7.  SOLE DISPOSITIVE POWER

    13,258,219

    8.  SHARED DISPOSITIVE POWER

    406,009

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    13,664,228

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.19%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    MannKind Corp.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1 Casper Street
    Danbury, CT 06810

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    56400P706

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $MNKD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNKD

    DatePrice TargetRatingAnalyst
    2/27/2026$3.50Outperform → Sector Perform
    RBC Capital Mkts
    11/24/2025Buy
    Truist
    11/13/2025$7.00Outperform
    Leerink Partners
    10/20/2025$10.00Overweight
    Wells Fargo
    10/10/2025$9.00Outperform
    Leerink Partners
    7/16/2025$9.00Buy
    H.C. Wainwright
    4/10/2025$12.00Outperform
    Mizuho
    2/10/2025$11.00Outperform
    Wedbush
    More analyst ratings

    $MNKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mannkind downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Mannkind from Outperform to Sector Perform and set a new price target of $3.50

    2/27/26 8:29:08 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Mannkind

    Truist initiated coverage of Mannkind with a rating of Buy

    11/24/25 8:30:57 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Mannkind with a new price target

    Leerink Partners initiated coverage of Mannkind with a rating of Outperform and set a new price target of $7.00

    11/13/25 9:09:54 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Friedman Michael A

    4 - MANNKIND CORP (0000899460) (Issuer)

    5/22/26 9:10:23 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Consiglio Ronald J was granted 10,000 shares, increasing direct ownership by 8% to 132,342 units (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    5/22/26 9:00:01 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Binder Steven B.

    4 - MANNKIND CORP (0000899460) (Issuer)

    5/22/26 8:56:12 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

    Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and enrollment of the first patient in the global Phase 2 INFLO-2 study. These milestones mark the advancement of the nintedanib DPI program and support its progression into mid-stage clinica

    6/3/26 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions

    5/29/26 2:00:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

    Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care by introducing a new inhaled mealtime insulin option recognized in the American Diabetes Association (ADA) Standards of Care alongside multiple daily injections (MDI) and insulin pumpsApproval is supported by results from the Phase 3 INHALE-1 study in pediatric patients, along with clinical efficacy and safety evidence generated across thousands of patients over the past 20+ years of Technosphere® inhaled insulin developmentEligible patients can access Afrezza today for $35 or less per month, with

    5/29/26 12:30:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Castagna Michael bought $259,000 worth of shares (100,000 units at $2.59), increasing direct ownership by 4% to 2,575,911 units (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    3/10/26 9:30:02 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    SEC Filings

    View All

    MannKind Corporation filed SEC Form 8-K: Other Events

    8-K - MANNKIND CORP (0000899460) (Filer)

    6/2/26 8:00:36 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation filed SEC Form 8-K: Other Events

    8-K - MANNKIND CORP (0000899460) (Filer)

    5/28/26 8:37:11 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - MANNKIND CORP (0000899460) (Filer)

    5/22/26 5:17:49 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Financials

    Live finance-specific insights

    View All

    MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions

    5/29/26 2:00:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

    Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M Program updates: Afrezza® pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026Nintedanib DPI (MNKD-201) for IPF advancing into Phase 2; INFLO-2 trial anticipates enrolling first patient in Q2 2026Ralinepag DPI (MNKD-1501) announced as collaboration program with United Therapeutics, received additional $5M to support accelerated development Conference call and webcast today at 4:30 p.m. ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026

    5/6/26 4:01:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, announced today that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a webcast beginning at 4:30 p.m. Eastern Time to review the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will be available in

    4/29/26 4:01:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    2/13/24 5:08:11 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    1/22/24 12:56:57 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    2/9/23 11:25:13 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Leadership Updates

    Live Leadership Updates

    View All

    MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today. Dr. Ahuja will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company's executive leadership team. "Ajay's deep expertise in medical affairs, clinical development, and global strategy—combined with his background as a practicing physician—will be instrumental as we continue to advance o

    9/29/25 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

    MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

    1/5/22 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care